LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Novocure Ltd

Open

BrancheGesundheitswesen

17.58 -1.12

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

17.43

Max

18.27

Schlüsselkennzahlen

By Trading Economics

Einkommen

-47M

-71M

Verkäufe

-295K

174M

EPS

-0.62

Gewinnspanne

-40.871

Angestellte

1,605

EBITDA

-29M

-63M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+46.23% upside

Dividenden

By Acuity

Nächstes Ergebnis

23. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

506M

2B

Vorheriger Eröffnungskurs

18.7

Vorheriger Schlusskurs

17.58

Nachrichtenstimmung

By Acuity

50%

50%

146 / 342 Ranking in Healthcare

Novocure Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Über Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat